Alzheimer's Test Results Delivered Digitally Didn't Increase Distress
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

The randomized eSMARTER trial found that people receiving Alzheimer’s genetic results through a digital platform had anxiety, disease-related distress and knowledge scores that met noninferiority criteria compared with a clinician telehealth appointment. Similar findings were reported for optional p-tau217 biomarker results. The study does not establish that digital disclosure suits every patient or replaces clinician support.

A randomized trial found that receiving Alzheimer’s genetic results through a digital platform was no worse than discussing them with a clinician by telehealth on measures of anxiety, disease-specific distress and disease-related knowledge. The eSMARTER findings, presented by Jessica Langbaum of Banner Alzheimer’s Institute at a Boston conference and published in JAMA Neurology, also showed similar results when participants received optional p-tau217 biomarker findings.

For listenersOffer from Amazon

Turn quiet afternoons into listening time

  • Thousands of audiobooks, podcasts and originals
  • Listen on your phone, tablet or Echo — also offline
  • Cancel anytime
Try Audible free Free trial for new members
As an affiliate, we earn on qualifying purchases.

The study randomized 651 adults ages 60 to 80 who had previously undergone APOE genotyping without learning the results through the GeneMatch research enrollment program. Of those participants, 216 received APOE results in a clinician-led telehealth session and 435 received them through a digital platform. Researchers assessed anxiety, Alzheimer’s-related distress and knowledge one to seven days after disclosure.

Across the full group, the results met the trial’s noninferiority standard: the digital approach was not worse than telehealth on the measured outcomes. Six months after receiving APOE findings, participants could choose to learn their plasma p-tau217 results using their assigned method. Langbaum reported similar findings for those disclosures, although the supplied report does not give detailed p-tau217 participant numbers or outcome estimates.

Most participants who received APOE findings carried an APOE4 variant: 58% were heterozygotes and 10% homozygotes, while 32% were noncarriers. Among APOE4 carriers, some measures modestly favored telehealth in the short term: disease-specific distress fell more, negative responses to learning risk were lower, and satisfaction was slightly higher. The differences were small, and the distress difference did not persist over time. Satisfaction was high in both groups.

At a glance
reportWhen: Presented November 21, 2026, at the Cli…
The developmentA randomized trial reported that digital delivery of Alzheimer’s genetic and biomarker test results did not produce worse short-term anxiety, disease-specific distress or knowledge outcomes than clinician-led telehealth disclosure.

Digital Results and Patient Support

The findings address a practical problem in how people receive test results. Under the 21st Century Cures Act, most medical test results must be made available to patients immediately. That can mean a person sees a result in a portal before having a scheduled appointment to discuss its meaning. Langbaum said patient portals often provide a static report or PDF with little context.

A digital tool designed to explain results could offer information at the moment patients see them and may give health systems another way to support patients between visits. The study suggests such a model can be an alternative to a telehealth disclosure for the outcomes tested, not that every patient should receive results without access to a clinician. The short-term differences among APOE4 carriers also underline why access to follow-up and individualized support remains relevant.

Products Worth Considering

Withings Body Smart Accurate Scale for Body Weight, Fat Percentage and Body Composition

Withings Body Smart Accurate Scale for Body Weight, Fat Percentage and Body Composition

As an affiliate, we earn on qualifying purchases.

How eSMARTER Tested Disclosure

Earlier research, as described in the MedPage Today report, found that disclosure of Alzheimer’s biomarkers was generally safe and well tolerated when a clinician led the discussion, either in person or remotely. eSMARTER compared that clinician-mediated approach with a patient-centered digital platform in a randomized trial.

Participants had internet access and passed psychological screening before enrollment. Their mean age was 68, and the mean Montreal Cognitive Assessment score was 19; about 36% scored below 19, a cutoff commonly used for cognitive impairment. Two-thirds of participants were women. All were offered optional digital educational materials about APOE and p-tau217 before disclosure. These eligibility conditions describe the study group and limit how directly the results can be applied to people with different support needs or circumstances.

“Learning Alzheimer’s genetic and biomarker information from a digital platform is no less effective—in other words, no worse than—receiving this information from a clinician telehealth visit.”

— Jessica Langbaum, PhD, Banner Alzheimer’s Institute

Limits of the Trial Findings

The results do not show that digital disclosure is appropriate for every patient, or that it can replace a clinician’s guidance in all cases. Participants were screened, had internet access and were enrolled through a research program, so the findings may not represent people who lack reliable connectivity or need more intensive support. The report also does not provide the precise noninferiority margins, full score estimates or detailed p-tau217 sample size.

It is also unclear from the reported findings how the platform would perform when incorporated into routine patient portals, where people may encounter results without preparing for them or having immediate access to a follow-up appointment. The study assessed anxiety, distress and knowledge; the reported findings do not establish effects on longer-term clinical decisions or health outcomes.

From Trial to Patient Portals

Langbaum said the results support developing a scalable platform that could connect with patient portals and provide explanations alongside test results. The study report does not specify a rollout schedule, identify a product or describe plans for a health-system implementation. Further work would need to clarify how digital disclosure can be paired with clinician follow-up and adapted for patients with different levels of digital access or support needs.

For now, the confirmed development is evidence from a randomized trial that digital disclosure met noninferiority criteria against telehealth on selected measures. Whether health systems adopt this approach, and how they would handle patients who want or need direct clinician discussion, remains to be determined.

Key Questions

What did the eSMARTER trial find?

For participants receiving APOE results, anxiety, Alzheimer’s-related distress and disease-related knowledge met the study’s noninferiority criteria for digital disclosure compared with clinician-led telehealth. Similar results were reported for optional p-tau217 disclosures.

Does the study show digital disclosure caused no distress?

No. It found no overall difference showing digital disclosure was worse than telehealth on the measured outcomes. Among APOE4 carriers, some short-term measures modestly favored telehealth, and the results do not mean that no individual experienced distress.

Who took part in the study?

The trial included 651 adults ages 60 to 80 who had previously had APOE genotyping without disclosure through the GeneMatch research program. Participants had internet access and passed psychological screening.

What is p-tau217?

It is a blood biomarker discussed in the study as a measure related to Alzheimer’s disease. Participants could choose to receive their plasma p-tau217 results six months after APOE disclosure; the supplied report does not provide detailed outcome estimates for that part of the trial.

Will digital results replace clinician appointments?

The findings do not establish that. Langbaum described digital tools as a possible way to provide context in patient portals and support patients. The study compared disclosure methods on selected measures, and plans for routine implementation were not reported.

Source: medpagetoday.com

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

How To Reduce Bedroom Allergens: What No One Told You (Home Comfort & Wellness Guide)

Discover surprising tips to reduce bedroom allergens and improve your sleep environment—learn what no one told you for ultimate home comfort and wellness.

Alzheimer’s Drug Pipeline: What I Learned At This Year’s CTAD Conference

Two late-stage Alzheimer’s trials missed their overall goals, while 2026 pipeline data show growing research into tau and inflammation.

Mitch McConnell remains hospitalized after more than three weeks

Senator Mitch McConnell has been hospitalized for more than three weeks following a health incident, with his condition still unclear. This update details the latest developments.

Probiotics and Gut Health: What Seniors Should Know

Gaining knowledge about probiotics and gut health helps seniors improve digestion, but understanding the full benefits can make a difference in your well-being.